Mesoblast Ltd has released a press release.
FDA Guidance on Clinical Pathway for LVAD Market Application
Filed with ASX ·
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
In the deck
Earlier from Mesoblast
- Appendix 4C - Quarterly, Strong Commercialization Revenues
- Circulation Research Highlights MSB Heart Failure Therapy
- FDA Grants Revascor Orphan Drug For End Stage CHF With LVADs
- MSB Expands JCR Partnership To Brain Disease In Newborns
- MSB Provides Q3 Financial Results and Operational Highlights
Later from Mesoblast
- Mesoblast Reports on Annual Results
- Grunenthal and MSB Enter Strategic Partnership for Back Pain
- Mesoblast Raises A$75 Million
- MSB and Lonza Enter GVHD Commercial Manufacturing Agreement
- MSB Provides Q1 Financial Results and Operational Highlights
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast